Technology is transforming the world and changing the way we do things. Until a few years ago developments like robotics, artificial intelligence and virtual reality were rarely to be found outside of science fiction, but many of them are now part of our everyday lives.
Investing in companies at the cutting edge of these new technologies offers a high return/high risk profile that might be suitable for younger investors with an active interest and good working knowledge of these areas.
The main danger is if the hype gets ahead of the reality, as is the case with some of the giant US tech companies and in particular the FANG stocks – Facebook, Amazon, Netflix and Google (now Alphabet) – where valuations have been bid up to ridiculous levels.
Fortunately it is a very different picture on this side of the pond where many small British tech companies have the potential to deliver structural growth in a low-growth world.
by Victor Hill| Equities| 10 mins. to read Oxford BioMedica may have a cure for leukaemia. Its share price has soared since the last week of June. Its treatment uses a modified version of the HIV virus to insert a cancer-killing gene into patients' cells. This is a stunning example of how gene therapy will revolutionise medicine in the future.
by John Kingham| Equities| 10 mins. to read AstraZeneca (LON:AZN) and GlaxoSmithKline (LON:GSK) are the two pharmaceutical giants of the FTSE 100. They are also both high yield dividend stocks with yields of more than 4%. Another notable fact is that both companies have been long-term holdings of a certain Mr Neil Woodford.
Material contained within Master Investor Magazine and its website is for general information purposes only and is not intended to be relied upon by individual readers in making (or refraining from making) any specific investment decisions. Master Investor Ltd. does not accept any liability for any losses suffered by any user as a result or any such decision.
Ingen kommentarer:
Send en kommentar